Sinomenine

Summary

Sinomenine (CHEMBL248095) is a phase-3 clinical-stage small molecule; indicated across 1 condition including osteoarthritis, knee.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• Indications: 1 condition
• Clinical trials: 1
• Chemistry: 329.4 Da · C19H23NO4

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL248095
Name	Sinomenine
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	5459308
Molecular formula	C19H23NO4
Molecular weight	329.4
InChIKey	INYYVPJSBIVGPH-QHRIQVFBSA-N

SMILES: CN1CC[C@@]23CC(=O)C(=C[C@@H]2[C@@H]1CC4=C3C(=C(C=C4)OC)O)OC

IUPAC name: (1R,9S,10S)-3-hydroxy-4,12-dimethoxy-17-methyl-17-azatetracyclo[7.5.3.01,10.02,7]heptadeca-2(7),3,5,11-tetraen-13-one

Also known as: Cucoline, Kukoline, Sinomenin, Sinomenine, SID85201028, sinomenine, SINOMENINE, SINOMENINE (CUCOLINE), Sinomenine (Cucoline), (-)-Sinomenine

Parent form; salt/anhydrous children: CHEMBL2133664

Patent coverage: 1,319 distinct patent families (2,143 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 2,129 (99%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 2 (assay-derived). Sample: Lethal(3)malignant brain tumor-like protein 1, Mas-related G-protein coupled receptor member X2.

Bioactivity

ChEMBL activities: 3 potent at pChembl ≥ 5 of 3 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
L3MBTL1	7.15	Potency	70.8	nM	CHEMBL_ACT_4615272
MRGPRX2	5.4	EC50	3981	nM	CHEMBL_ACT_26241686
MRGPRX2	5.27	EC50	5370	nM	CHEMBL_ACT_26241802

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 indication (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
osteoarthritis, knee	3	MONDO:0005416	EFO:0004616

Clinical trials

Total trials: 1.

Phase distribution

Phase	Trials
PHASE3	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT05764304	PHASE3	UNKNOWN	Sinomenine Versus Glucocorticoid for Knee OA

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).